FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 20, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
ERα+ Breast CancerESR1 Gene Mutation
Interventions
DRUG

Tamoxifen

estrogen modulator

DIAGNOSTIC_TEST

FES PET/CT

Radiolabeled estrogen \[18F\]-fluoroestradiol (FES) in combination with Positron Emission Tomography / Computed Tomography is a molecular imaging technique for measuring pharmacodynamic effects of endocrine therapy. The injected dose of 18F-FES will be 6 mCi (185 MBq) ± 20% with a specific activity greater than 170 Ci/mmol at the time of injection for an activity dose of 6 mCi. Participant will receive baseline imaging and repeat imaging after 3-4 weeks to evaluate for FES blockade as assigned dose level.

Trial Locations (2)

53792

RECRUITING

University of Wisconsin Carbone Cancer Center, Madison

NOT_YET_RECRUITING

Wisconsin Oncology Network (WONIX) sites, Madison

All Listed Sponsors
lead

University of Wisconsin, Madison

OTHER